QCM

Givinostat

Created: 2019-10-15
Last modified:  2020-06-05

Find related ligands:

Chemical Details

Formal Charge0
Atom Count58
Chiral Atom Count0
Bond Count60
Aromatic Bond Count17
2D diagram of QCM

Chemical Component Summary

NameGivinostat
Synonyms{6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate
Systematic Name (OpenEye OEToolkits)[6-(diethylaminomethyl)naphthalen-2-yl]methyl ~{N}-[4-(oxidanylcarbamoyl)phenyl]carbamate
FormulaC24 H27 N3 O4
Molecular Weight421.489
TypeNON-POLYMER

Chemical Descriptors

TypeProgram Version Descriptor
SMILESACDLabs12.01C(c3ccc(NC(OCc1ccc2c(c1)ccc(c2)CN(CC)CC)=O)cc3)(NO)=O
SMILESCACTVS3.385CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1
SMILESOpenEye OEToolkits2.0.7CCN(CC)Cc1ccc2cc(ccc2c1)COC(=O)Nc3ccc(cc3)C(=O)NO
Canonical SMILESCACTVS3.385 CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1
Canonical SMILESOpenEye OEToolkits2.0.7 CCN(CC)Cc1ccc2cc(ccc2c1)COC(=O)Nc3ccc(cc3)C(=O)NO
InChIInChI1.03 InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)
InChIKeyInChI1.03 YALNUENQHAQXEA-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank IDDB12645 
NameGivinostat
Groups
  • investigational
  • approved
DescriptionGivinostat is a small molecule histone deacetylase (HDAC) inhibitor. It has been investigated as a treatment for a variety of inflammatory diseases, like Crohn's disease and juvenile idiopathic arthritis, cancers like leukemia and lymphoma, as well as several muscular dystrophies. In the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss.[L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD).[L50311,L50316] It is the first non-steroidal drug approved to treat patients with all genetic variants of DMD.[L50316]
Synonyms
  • Givinostat
  • Givinostat hydrochloride monohydrate
Brand NamesDuvyzat
IndicationGivinostat is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients ≥6 years of age.[L50311]
Categories
  • Acids, Acyclic
  • Amines
  • Antineoplastic Agents
  • Cytochrome P-450 CYP1A2 Inducers
  • Cytochrome P-450 CYP1A2 Inducers (strength unknown)
ATC-CodeM09AX14
CAS number497833-27-9

Drug Targets

NameTarget SequencePharmacological ActionActions
Histone deacetylaseMAQTQGTRRKVCYYYDGDVGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRK...unknowninhibitor
Tyrosine-protein kinase JAK2MGMACLTMTEMEGTSTSSIYQNGDISGNANSMKQIDPVLQVYLYHSLGKS...unknowninhibitor
Histone deacetylase 1MAQTQGTRRKVCYYYDGDVGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRK...unknowninhibitor
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknowninhibitor,inducer
Cytochrome P450 1A2MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...unknowninducer
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL1213492
PubChem 9804992
ChEMBL CHEMBL1213492
ChEBI CHEBI:94187